eNOS Decoy Peptides for VILI Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ventilator-induced lung injury (VILI) and acute respiratory distress syndrome (ARDS) lack effective therapeutic options to mitigate the pathophysiological processes associated with increased vascular permeability, leading to high morbidity and mortality.
Innovation Solution
Development of synthetic peptides that act as decoys for endothelial nitric oxide synthase (eNOS) to prevent phosphorylation and uncoupling, thereby preserving endothelial cell barrier function by binding to Protein Kinase C (PKC) and reducing reactive oxygen species generation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mechanical ventilation is used to treat respiratory failure, then patient survival is improved, but ventilator-induced lung injury occurs due to excessive mechanical stress
Solution Approach 1:
The patent introduces a small molecule compound as an intermediary that targets and inhibits the PKC-eNOS signaling pathway. This mediator blocks the harmful transmission of mechanical stress signals from the ventilator to the lung tissue, preventing the initiation of inflammatory cascades while allowing the ventilator to continue providing necessary respiratory support.
Solution Approach 2:
The invention applies preliminary anti-action by administering the PKC inhibitor before or at the onset of mechanical ventilation to prevent VILI before it develops. The compound pre-emptively blocks the phosphorylation of eNOS at Thr495, thereby preventing the downstream inflammatory response and endothelial barrier disruption that would otherwise be triggered by mechanical stress during ventilation.
2Object-affected harmful factors
If protective lung ventilation strategies are used, then lung injury is reduced, but these strategies are only supportive and not therapeutic
Solution Approach 1:
The patent replaces the purely mechanical protective ventilation approach with a pharmacological intervention. Instead of relying solely on mechanical parameters (tidal volume, PEEP) to mitigate injury, the invention introduces a biochemical mechanism (PKC inhibition) that actively counteracts the pathophysiological processes of VILI, transforming supportive care into therapeutic treatment.
Solution Approach 2:
The invention changes the therapeutic parameter from mechanical ventilation settings to molecular pathway inhibition. By targeting the PKC-eNOS signaling axis at the molecular level, the treatment addresses the root biochemical mechanisms of VILI (inflammatory cytokine production, endothelial barrier disruption) rather than merely managing mechanical parameters, thereby providing genuine therapeutic effect.
3Productivity
If eNOS phosphorylation at Thr495 is increased, then inflammatory cytokine expression is upregulated, but this leads to increased vascular permeability and lung injury
Solution Approach 1:
The patent extracts and isolates the critical phosphorylation event (eNOS at Thr495) as the specific therapeutic target. By designing a PKC inhibitor that selectively blocks this phosphorylation site, the invention removes the triggering event that initiates the harmful inflammatory cascade, thereby preventing both excessive cytokine production and vascular permeability without affecting other physiological processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The eNOS decoy peptides effectively reduce vascular permeability, inflammation, and lung injury in both in vitro and in vivo models of VILI, demonstrating potential for treating VILI and other vascular permeability-related diseases.
Implementation Method 1
PKC-dependent phosphorylation of eNOS at Threonine 495 (T495)
Implementation Method 2
followed by increased reactive oxygen species generation
Data Source
AI summary
It has been discovered that phosphorylation-dependent uncoupling of endothelial nitric oxide synthase (eNOS) plays an important role in endothelial cell (EC) barrier disruption. Compositions and methods to reduce or prevent eNOS uncoupling are disclosed. Decoy peptides that can prevent phosphorylation and mitochondrial redistribution of eNOS, reduce eNOS uncoupling, and preserve EC barrier function, and uses thereof, are described. The peptides improve lung vascular integrity in a mouse model of VILI. Thus, the decoy peptides can be used to treat or prevent diseases or disorders associated with increased vascular permeability such as ALI, ARDS, and VILI.